Media stories about Benitec Biopharma Limited (NASDAQ:BNTC) have trended somewhat positive this week, according to Accern Sentiment. Accern identifies negative and positive media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Benitec Biopharma Limited earned a daily sentiment score of 0.22 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 46.2665719780013 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

Shares of Benitec Biopharma Limited (NASDAQ:BNTC) remained flat at $2.17 on Monday. The company’s stock had a trading volume of 242 shares. The firm’s market cap is $22.26 million. The stock’s 50 day moving average is $2.08 and its 200 day moving average is $2.33. Benitec Biopharma Limited has a one year low of $1.30 and a one year high of $5.48.

A number of research firms recently issued reports on BNTC. ValuEngine raised shares of Benitec Biopharma Limited from a “sell” rating to a “hold” rating in a report on Friday, September 22nd. Maxim Group reaffirmed a “hold” rating on shares of Benitec Biopharma Limited in a report on Wednesday, August 30th.

COPYRIGHT VIOLATION NOTICE: “Somewhat Positive Press Coverage Somewhat Unlikely to Impact Benitec Biopharma Limited (BNTC) Share Price” was originally published by Watch List News and is owned by of Watch List News. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The correct version of this report can be viewed at

Benitec Biopharma Limited Company Profile

Benitec Biopharma Limited is a biotechnology company. The Company is engaged in progressing programs through the clinic; the commercialization of its Intellectual Property (IP); development of its therapeutic pipeline and pre-clinical programs, and funding, and protecting and building the IP estate. Its In-house product candidates include TT-034, BB-HB-331, BB-AMD-211 and ddRNAi therapeutic.

Insider Buying and Selling by Quarter for Benitec Biopharma Limited (NASDAQ:BNTC)

Receive News & Ratings for Benitec Biopharma Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Benitec Biopharma Limited and related companies with Analyst Ratings Network's FREE daily email newsletter.